MEF2 transcription factors: developmental regulators and emerging cancer genes

Pon, Julia R.; Marra, Marco A.

doi:10.18632/oncotarget.6223

Cited by 144 publications

(120 citation statements)

References 152 publications

Supporting

Mentioning

118

Contrasting

Order By: Relevance

“…The MEF2 transcription factors serve roles in muscular, cardiac, skeletal, vascular, neural, blood and immune cell development through their effects on cell differentiation, proliferation, apoptosis, migration, morphology and metabolism (30). Altered MEF2 activity serves a role in human diseases and it has recently been implicated in the initiation and progression of various types of cancer in humans (31).…”

Section: Discussionmentioning

confidence: 99%

Downregulation of miR‑30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer

Zhao

Shu

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Accumulating studies have revealed that microRNAs serve crucial roles in cancer development and progression. MicroRNA-30a (miR-30a) has been implicated in various cancer types. However, the role of miR-30a in cervical cancer remains unclear. In the current study, a reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay revealed that miR-30a was significantly downregulated in cervical cancer tissues compared with adjacent normal tissues, and in the cervical cancer cell lines HeLa, SiHa and Ca-Ski compared with GH329 normal cervical epithelial cells. A functional assay using miR-30a mimic demonstrated that miR-30a could inhibit the growth and invasion of cervical cancer cells. Additionally, bioinformatics-based prediction and luciferase reporter assays indicated that MEF2D is a direct target of miR-30a. Transfection with miR-30a reduced the mRNA expression and protein levels of MEF2D, as determined using RT-qPCR and western blot analyses. Furthermore, MEF2D expression was negatively correlated with that of miR-30a in cervical cancers. Overall, the present study demonstrated that miR-30a functions as a tumor suppressor by targeting MEF2D in cervical cancer, which may provide the basis for a prognostic biomarker or therapeutic strategy for cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Downregulation of miR‑30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer

Zhao

Shu

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Only locus showed borderline significance in our meta‐analysis dataset ( P =.011), with concordant risk effects in both studies and each individual cohort; it includes the PRRX1 gene, a putative MEF2 target involved in the development of diverse muscle types . MEF2 family, important regulators of muscular, neural, and immune system development . Of note, among other defects, subjects with MEF2C report abnormalities of GI motility, including gastroesophageal reflux disease, dysphagia, and constipation …”

Section: Discussionmentioning

confidence: 99%

“…MEF2 family, important regulators of muscular, neural, and immune system development . Of note, among other defects, subjects with MEF2C report abnormalities of GI motility, including gastroesophageal reflux disease, dysphagia, and constipation …”

Section: Discussionmentioning

confidence: 99%

A meta‐analysis of reflux genome‐wide association studies in 6750 Northern Europeans from the general population

Bonfiglio

Hysi

et al. 2016

Neurogastroenterology Motil

View full text Add to dashboard Cite

show abstract

“…Altered MEF2 activity has been revealed as driver of cancer development, including both hematological cancers and solid tumor. Recent study found that MEF2 genes might act as oncogenes in NSCLC [12]. …”

Section: Introductionmentioning

confidence: 99%

Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer

et al. 2017

View full text Add to dashboard Cite

BackgroundLung cancer is the leading cause of cancer-related morbidity and mortality worldwide. Patients with chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), are exposed to a higher risk of developing lung cancer. Chronic inflammation may play an important role in the lung carcinogenesis among those patients. The present study aimed at identifying candidate biomarker predicting lung cancer risk among patients with chronic respiratory diseases.MethodsWe applied clinical bioinformatics tools to analyze different gene profile datasets with a special focus on screening the potential biomarker during chronic inflammation-lung cancer transition. Then we adopted an in vitro model based on LPS-challenged A549 cells to validate the biomarker through RNA-sequencing, quantitative real time polymerase chain reaction, and western blot analysis.ResultsBioinformatics analyses of the 16 enrolled GSE datasets from Gene Expression Omnibus online database showed myocyte enhancer factor 2D (MEF2D) level significantly increased in COPD patients coexisting non-small-cell lung carcinoma (NSCLC). Inflammation challenge increased MEF2D expression in NSCLC cell line A549, associated with the severity of inflammation. Extracellular signal-regulated protein kinase inhibition could reverse the up-regulation of MEF2D in inflammation-activated A549. MEF2D played a critical role in NSCLC cell bio-behaviors, including proliferation, differentiation, and movement.ConclusionsInflammatory conditions led to increased MEF2D expression, which might further contribute to the development of lung cancer through influencing cancer microenvironment and cell bio-behaviors. MEF2D might be a potential biomarker during chronic inflammation-lung cancer transition, predicting the risk of lung cancer among patients with chronic respiratory diseases.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-017-1168-x) contains supplementary material, which is available to authorized users.

show abstract

MEF2 transcription factors: developmental regulators and emerging cancer genes

Abstract: ABSTRACT

Cited by 144 publications

References 152 publications

Downregulation of miR‑30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer

Downregulation of miR‑30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer

A meta‐analysis of reflux genome‐wide association studies in 6750 Northern Europeans from the general population

Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer

Contact Info

Product

Resources

About